Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matinas BioPharma ( (MTNB) ) has provided an announcement.
On December 12, 2025, Matinas BioPharma Holdings, Inc. amended its employment agreement with CEO Jerome D. Jabbour, extending the deadline for a Change in Control to June 30, 2026, and modifying the payment structure for his retention bonus. The amendment also includes changes to the definitions of ‘Change in Control,’ ‘Cause,’ and ‘Good Reason,’ impacting the terms under which Mr. Jabbour can receive his bonus, reflecting strategic adjustments in the company’s executive compensation plan.
Spark’s Take on MTNB Stock
According to Spark, TipRanks’ AI Analyst, MTNB is a Neutral.
The overall score reflects significant financial challenges due to declining revenues and persistent losses. Positive technical indicators provide some optimism, while valuation remains unattractive with a negative P/E ratio and no dividend yield. The recent board appointments may offer strategic improvements, but substantial progress is needed to improve financial health and stock performance.
To see Spark’s full report on MTNB stock, click here.
More about Matinas BioPharma
Matinas BioPharma Holdings, Inc. operates in the biopharmaceutical industry, focusing on developing innovative therapies for various medical conditions.
Average Trading Volume: 37,150
Technical Sentiment Signal: Sell
Current Market Cap: $5.06M
For a thorough assessment of MTNB stock, go to TipRanks’ Stock Analysis page.